Division of Bristol-Myers Squibb Co.
Latest From Medarex Inc.
Research and early development head Rupert Vessey, who had a similar role at Celgene, told Scrip that integration of the company’s pipeline into Bristol is nearly complete with few overlapping programs.
PD-1 discoverer and the Japanese co-developer of Opdivo remain locked in simmering dispute over patent royalties, with a revised one-off settlement or legal action emerging as possible near-term options.
The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.
The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
Howard H Pien, Pres. & CEO
Christian S Schade , SVP, Fin. & Admin. & CFO
Ronald A Pepin, PhD, SVP, Bus. Dev.
- Contact Info
Phone: (609) 430-2880
707 State Rd.
P.O. Box 930 Princeton, NJ 08540-1437
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.